Latest Myeloproliferative disease Stories
SEATTLE, Dec. 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
SEATTLE, Aug. 7, 2014 /PRNewswire/ --CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S.
MILWAUKEE, July 23, 2014 /PRNewswire-USNewswire/ -- BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of a
-Top-line Results Expected in Early 2015- SEATTLE, July 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
HILDEN, Germany and VIENNA, April 10, 2014 /PRNewswire/ -- - Reliable diagnostic tools under development for mutations of calreticulin
Melbourne researchers have solved a puzzle as to how an essential blood-making hormone stimulates production of the blood clotting cells known as platelets.
ASHEVILLE, N.C., March 28, 2014 /PRNewswire/ -- It's hard to imagine heavyweight hematologists publicly squaring off in support of an off-label blood cancer drug.
- This Trial, Together with PERSIST-1, to Support Registration in the U.S. and Europe - SEATTLE, March 3, 2014 /PRNewswire/ -- Cell Therapeutics, Inc.
Following the discovery of the Calreticulin (CALR) mutation, which accounts for the majority of non JAK/MPL mutations in ET and MF patients, Dr.
FT. MYERS, Fla., Jan. 7, 2014 /PRNewswire/ -- NeoGenomics, Inc.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.